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Abstract
Background: Type 2 diabetes and the metabolic syndrome are associated with impaired diastolic function and
increased heart failure risk. Animal models and autopsy studies of diabetic patients implicate myocardial fibrosis,
cardiomyocyte hypertrophy, altered myocardial microvascular structure and advanced glycation end-products
(AGEs) in the pathogenesis of diabetic cardiomyopathy. We investigated whether type 2 diabetes and the
metabolic syndrome are associated with altered myocardial structure, microvasculature, and expression of AGEs
and receptor for AGEs (RAGE) in men with coronary artery disease.
Methods: We performed histological analysis of left ventricular biopsies from 13 control, 10 diabetic and 23
metabolic syndrome men undergoing coronary artery bypass graft surgery who did not have heart failure or atrial
fibrillation, had not received loop diuretic therapy, and did not have evidence of previous myocardial infarction.
Results: All three patient groups had similar extent of coronary artery disease and clinical characteristics, apart
from differences in metabolic parameters. Diabetic and metabolic syndrome patients had higher pulmonary
capillary wedge pressure than controls, and diabetic patients had reduced mitral diastolic peak velocity of the
septal mitral annulus (E’), consistent with impaired diastolic function. Neither diabetic nor metabolic syndrome
patients had increased myocardial interstitial fibrosis (picrosirius red), or increased immunostaining for collagen I
and III, the AGE Nε-(carboxymethyl)lysine, or RAGE. Cardiomyocyte width, capillary length density, diffusion radius,
and arteriolar dimensions did not differ between the three patient groups, whereas diabetic and metabolic
syndrome patients had reduced perivascular fibrosis.
Conclusions: Impaired diastolic function of type 2 diabetic and metabolic syndrome patients was not dependent
on increased myocardial fibrosis, cardiomyocyte hypertrophy, alteration of the myocardial microvascular structure,
or increased myocardial expression of Nε-(carboxymethyl)lysine or RAGE. These findings suggest that the increased
myocardial fibrosis and AGE expression, cardiomyocyte hypertrophy, and altered microvasculature structure
described in diabetic heart disease were a consequence, rather than an initiating cause, of cardiac dysfunction.
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advanced glycation end-products
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Type 2 diabetes and the metabolic syndrome (MetS) are
associated with impaired diastolic function and an
increased risk of heart failure [1,2]. There is increasing
evidence for a specific diabetic cardiomyopathy, inde-
pendent of coronary artery disease and hypertension,
and a similar mechanism may account for the increased
heart failure risk associated with the MetS [1-6]. Myo-
cardial fibrosis and cardiomyocyte hypertrophy are the
most frequently proposed mechanisms for the impaired
diastolic function of diabetes, and morphological
changes in small vessels of the diabetic myocardium and
reduced capillary length density have also been
described [1,2,5]. In addition, advanced glycation end-
products (AGEs) are proposed to contribute to diabetic
cardiomyopathy by cross-linking myocardial proteins
such as collagen and elastin, and by promoting collagen
accumulation [7]. Evidence for these mechanisms comes
mainly from rodent models of diabetes [7-11], and the
increased myocardial fibrosis in rodent models has led
to the development of genetic models to examine its
pathogenesis and to test antifibrotic therapies [8,9].
There is, however, uncertainty about the role of these
mechanisms in the human diabetic heart. There are
reports of increased interstitial fibrosis and collagen
deposition [12-16], and reports of no difference in fibro-
sis between diabetic and non-diabetic hearts [17-19],
although the impact of diabetes on fibrosis may depend
on concomitant hypertension [18]. A key limitation of
previous studies of the human diabetic heart is that
many were small autopsy studies of end-stage disease
that did not allow separation of the effects of diabetes
from those of co-morbidities including heart failure and
renal disease [3,12,14,16,18,20]. Non-autopsy studies
included patients with impaired left ventricular (LV)
function and heart failure [17,21-23], and there is uncer-
tainty whether the changes observed were the cause or
the consequence of impaired cardiac function.
The present study was undertaken to investigate the
association of type 2 diabetes and the MetS with myo-
cardial fibrosis, cardiomyocyte size, capillary length den-
sity, diffusion radius, arteriolar dimensions, and
myocardial expression of the advanced glycation end-
product (AGE) Nε-(carboxymethyl)lysine (CML) and the
receptor for AGEs (RAGE). We obtained LV biopsies
from patients without heart failure or previous myocar-
dial infarction who were undergoing coronary artery
bypass graft surgery. By comparing MetS (pre-diabetic)
and diabetic patients with control patients without these
conditions, we examined the effects of the insulin-resis-
tant state before diabetes (and anti-diabetes medication)
commenced, and the effects of diabetes before heart fail-
ure developed. Although we obtained LV biopsies from
both men and women, preliminary analysis showed gen-
der-specific differences in myocardial structure [24];
therefore, given the smaller number of women recruited
to this study, the present analysis was confined to men.
Methods
Patients
Details of the Cardiac Tissue Bank have been previously
d e s c r i b e d[ 2 4 ] .T h eS t .V i n c e n t ’sH e a l t hH u m a n
Research Ethics Committee approved this research and
all patients gave written informed consent. From the
Tissue Bank we selected all of 46 male patients having
coronary artery bypass graft surgery alone, who did not
have heart failure or atrial fibrillation, had not received
loop diuretic therapy, and did not have evidence of pre-
vious myocardial infarction. Absence of previous myo-
cardial infarction was established from the clinical
history, electrocardiogram and troponin measurements,
and was confirmed by inspection of the ventriculogram,
transthoracic and transesophageal echocardiography,
and examination of the heart at surgery. All patients
had normal or near-normal LV systolic function as
assessed by pre-operative transthoracic echocardiogra-
phy and/or ventriculogram, with LV ejection fraction ≥
50%. Intra-operative hemodynamics were measured after
induction of anesthesia. A partial-thickness wedge-
shaped biopsy was taken during surgery, immediately
after cardioplegia, from a region of the lateral wall of
the LV near the base of the heart, between the terri-
tories of the left anterior descending and circumflex
arteries, that was free of any macroscopic pathology,
without evidence of ischemia or wall motion abnormal-
ity on pre-operative or intra-operative imaging studies,
as previously described [24].
Of the 46 patients, 13 control patients had neither
MetS nor diabetes, 10 had type 2 diabetes, and 23 had
MetS. MetS was defined according to the International
Diabetes Federation [25]. For patients in whom abdom-
inal circumference was not measured, based on the rela-
tionship between abdominal circumference and BMI
[26], those with BMI > 25 kg/m
2 were considered to
exceed the abdominal circumference threshold for
MetS. A patient had diabetes if a history of diabetes was
evident from use of glucose-lowering medications and/
or insulin or if fasting plasma glucose was ≥ 7 mmol/L
[27]. Of the 10 patients with diabetes, two were newly
diagnosed and treated with diet alone, three were trea-
ted with insulin alone, two with insulin and metformin,
two with metformin and gliclazide, and one with glicla-
zide alone. The mean duration of diabetes was 12 (range
0-30) years and the mean HbA1 c was 7.3% (range 5.3-
9.8%, n = 7). HbA1 c was not measured routinely as
part of patient enrolment in the Tissue Bank, and 3
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Page 2 of 14patients did not have recent HbA1 c measurement
before surgery.
Biochemistry
Blood Hb and HbA1c, and plasma levels of creatinine
were measured as part of the routine pre-surgery
workup. All other variables were measured on fasting
blood collected on the day of surgery, before induction
of anesthesia. Blood Hb and HbA1c, and plasma levels
of glucose, insulin, lipids, and creatinine were measured
by St. Vincent’s Health Pathology using routine clinical
methods. Estimated glomerular filtration rate (eGFR)
was calculated from the Modification of Diet in Renal
Disease formula [28]. Insulin resistance (HOMA2-IR),
insulin sensitivity (HOMA2-%S), and b-cell function
(HOMA2-%B), were calculated using the HOMA calcu-
lator version 2.2 [29]. CML was measured by ELISA
(Microcoat, Penzberg, Germany). Low molecular weight
fluorophores (LMWF) were measured by fluorescence
spectroscopy [30]. Soluble RAGE was measured by
ELISA (R&D Systems Inc., Minneapolis, MN). Amino-
terminal-pro-B-type natriuretic peptide (NT-proBNP)
was measured by electrochemiluminescence immunoas-
say using an Elecsys instrument (Roche Diagnostics,
Basel, Switzerland).
Histological analysis
Details of tissue collection and fixation have been pre-
viously described [24]. All histological analyses were per-
formed blind to patient identity and group allocation.
Picrosirius red-stained 4 μm paraffin sections were ana-
lyzed for interstitial and perivascular fibrosis and arterio-
lar dimensions by quantitative morphometry of digitized
images of the whole myocardial section (Aperio Tech-
nologies, Inc., CA). Myocardial total fibrosis was calcu-
lated using the positive pixel count algorithm as the
area of collagen staining expressed as a percentage of
the total myocardial tissue area, after excluding the peri-
cardium, whereas interstitial fibrosis was calculated as
described for total fibrosis, with exclusion of perivascu-
lar fibrosis.
Perivascular fibrosis was calculated as the ratio of the
area of perivascular fibrosis to the total vessel area (area
of vessel wall plus lumen) as determined by planimetry
[31], for arterioles with mean diameter (average of maxi-
mum and minimum diameter of each arteriole) of 39
μm (range 12-151 μm). Arteriolar wall area/circumfer-
ence ratio was measured for arterioles with mean aver-
age diameters of 20-80 μm. Cardiomyocyte width,
determined on 4 μm sections of paraffin-embedded tis-
sue stained for reticulin [32], was the mean of > 100
measurements for each section of the shortest diameter
of cardiomyocyte profiles containing a nucleus. Mea-
surement of capillary length density, which is the length
of capillaries per unit volume of tissue, has been pre-
viously described [24].
Immunohistochemistry for collagen I and collagen III
was performed in frozen sections using mouse monoclo-
nal antibodies ab6308 and ab6310 (Abcam, Cambridge,
UK), respectively. Myocardial total collagen I and col-
lagen III densities were calculated using the positive
pixel count algorithm (Aperio Technologies, Inc., CA)
as the area of collagen staining expressed as a percen-
tage of the total myocardial tissue area, after excluding
the pericardium. Immunohistochemistry for CML was
performed in paraffin sections using a mouse monoclo-
nal antibody as described by Schalkwijk et al. [33].
Immunohistochemistry for RAGE was performed with a
goat polyclonal antibody AB5484 (Millipore, Billerica,
MA). Immunostaining of arteriolar media and intima for
CML and of arteriolar intima and capillaries for RAGE
was individually scored by its intensity as 0+, 1+, 2+, or
3+, after inspection of the digitized image of the whole
of each section.
Statistical analysis
The significance of differences between study groups
was determined by analysis of variance (ANOVA) for
continuous variables and Fisher’s exact test for categori-
cal variables. Continuous data were logarithmically
transformed when necessary to normalize variances. The
Fisher’s Protected Least Significant Difference test and
the Bonferroni correction were used for multiple com-
parisons of continuous and categorical variables, respec-
tively. Correlations were estimated using Pearson
correlation coefficients. All tests were two-tailed. Differ-
ences were considered significant at P < 0.05.
Results
Patient characteristics
Patient characteristics are shown in Table 1. The three
patient groups were of mean age 63-66 years, with similar
extent of coronary artery disease, occluded coronary
arteries, collaterals, and numbers of coronary grafts per-
formed. Diabetic patients had increased plasma glucose
levels and both MetS and diabetic patients had increased
BMI, plasma triglyceride levels, fasting plasma insulin,
reduced insulin sensitivity and increased insulin resistance.
Diabetic patients also had increased plasma creatinine and
reduced eGFR. The three patient groups otherwise had
similar clinical and biochemical characteristics, with simi-
lar plasma C-reactive protein, NT-proBNP, CML, LMWF,
and soluble RAGE levels, and received similar therapies,
apart from anti-diabetic therapies.
Hemodynamics and echocardiography
Whereas cardiac index was not different between the
three patient groups, MetS patients had higher central
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Page 3 of 14Table 1 Characteristics of control, metabolic syndrome, and diabetic men undergoing coronary artery bypass graft
surgery
Parameter Control Metabolic
syndrome
Diabetic
n1 3 2 3 1 0
Age, years 66 ± 2 63 ± 2 66 ± 3
Left main stenosis > 50%, n (%) 6 (46%) 15 (65%) 3 (30%)
One vessel stenosis > 70%, n (%) 3 (23%) 6 (26%) 1 (10%)
Two vessel stenosis > 70%, n (%) 7 (54%) 11 (48%) 6 (60%)
Three vessel stenosis > 70%, n (%) 3 (23%) 5 (22%) 3 (30%)
Patients with occluded coronary artery, n (%) 5 (38%) 7 (30%) 5 (50%)
Coronary collaterals, Rentrop grade 2 or 3, n (%) 5 (38%) 12 (52%) 5 (50%)
Previous percutaneous transluminal coronary angioplasty, n (%) 2 (15%) 4 (17%) 1 (10%)
Wall motion abnormality, n (%) 2 (15%) 2 (9%) 1 (10%)
Coronary grafts/patient, n 3.4 ± 0.3 3.4 ± 0.2 3.6 ± 0.2
BMI (kg/m
2) 25.3 ± 0.8 30.1 ± 0.7* 30.2 ± 1.3†
BSA (m
2) 1.93 ± 0.05 2.06 ± 0.03† 2.05 ± 0.06
Clinical risk factors
Pre-admission systolic blood pressure (mmHg) 127 ± 3 134 ± 3 133 ± 4
Pre-admission diastolic blood pressure (mmHg) 74 ± 2 76 ± 2 77 ± 3
Previous hypertension, n (%) 7 (54%) 20 (87%) 8 (80%)
Ever smoked, n (%) 7 (54%) 15 (65%) 6 (60%)
Fasting plasma total cholesterol (mmol/L) 3.5 ± 0.2 3.7 ± 0.3 3.1 ± 0.2
Fasting plasma LDL cholesterol (mmol/L) 2.1 ± 0.2 2.2 ± 0.2 1.7 ± 0.2
Fasting plasma HDL cholesterol (mmol/L) 1.03 ± 0.04 0.93 ± 0.05 0.88 ± 0.06
Fasting plasma triglyceride (mmol/L) 1.08 ± 0.04 2.02 ± 0.21* 1.86 ± 0.26†
Fasting plasma glucose (mmol/L) 5.6 ± 0.2 5.9 ± 0.1 8.1 ± 0.5‡,§
Fasting plasma insulin (pmol/L) 45 ± 11 84 ± 11* 149 ± 53‡
b cell function from HOMA2-%B 65 ± 11 92 ± 9 67 ± 11
Insulin sensitivity from HOMA2-%S 167 ± 22 90 ± 11‡ 65 ± 14‡
Insulin resistance from HOMA2-IR 0.8 ± 0.2 1.5 ± 0.2* 2.5 ± 0.7‡
Plasma CML (μmol/L) 2.0 ± 0.2 2.2 ± 0.1 2.2 ± 0.1
Plasma LMWF (AU/mL) 2.6 ± 0.2 2.6 ± 0.2 2.8 ± 0.3
Plasma soluble RAGE (pg/mL) 604 ± 96 642 ± 60 753 ± 108
Plasma NT-proBNP (pmol/L) 16 ± 4 14 ± 2 24 ± 6
Hb (g/L) 14.4 ± 0.3 14.8 ± 0.3 13.3 ± 0.6||
Plasma creatinine (μmol/L) 91 ± 4 91 ± 4 105 ± 4†,||
eGFR (mL/min per 1.73 m
2) 7 4±4 7 6±3 6 3±3 †,||
C-reactive protein (mg/L) 2.7 ± 0.9 5.5 ± 2.2 3.6 ± 1.2
Medications
ACE inhibitor therapy, n (%) 5 (38%) 11 (48%) 8 (80%)
ARB therapy, n (%) 2 (15%) 8 (35%) 1 (10%)
ACEI and/or ARB therapy, (%) 7 (54%) 18 (78%) 9 (90%)
Statin therapy, n (%) 11 (85%) 20 (87%) 9 (90%)
Aspirin therapy, n (%) 7 (54%) 14 (61%) 5 (50%)
Calcium antagonist therapy, n (%) 2 (15%) 6 (26%) 2 (20%)
b-blocker therapy, n (%) 11 (85%) 15 (65%) 7 (70%)
Long-acting nitrate therapy, n (%) 1 (8%) 4 (17%) 5 (50%)
Thiazide or indapamide therapy, n (%) 3 (23%) 4 (17%) 3 (30%)
Data shown as means ± SEM or n (%). *p < 0.01; †p < 0.05; ‡p < 0.001 in comparison with control; §p < 0.001; ||p < 0.05 in comparison with metabolic
syndrome. One metabolic syndrome patient with left main stenosis > 50% did not have other vessel stenosis > 70%. Coronary collaterals were scored according
to Rentrop et al. [48]. ARB, angiotensin receptor blocker; CML, Nε-(carboxymethyl)lysine; eGFR, estimated glomerular filtration rate calculated using the
Modification of Diet in Renal Disease study equation [28]; HOMA, Homeostasis Model Assessment calculator version 2.2 [29]; LMWF, low molecular weight
fluorophore; NT-proBNP, amino-terminal-pro-B-type natriuretic peptide; RAGE, receptor for advanced glycation end-products.
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Page 4 of 14venous pressure than control patients. Because of the
close correlation between central venous pressure and
pulmonary capillary wedge pressure (r = 0.80, P <
0.0001), pulmonary capillary wedge pressure data were
analyzed with central venous pressure as a covariate,
and both MetS and diabetic patients had higher pul-
monary capillary wedge pressures than control patients,
consistent with impaired diastolic function (Figure 1).
Pre-operative transthoracic echocardiography, performed
by either the referring institution or by St. Vincent’s
Health, was not performed in all patients. MetS patients
had slightly higher LV ejection fraction than control and
diabetic patients (Figure 2). Control, MetS, and diabetic
patients had similar left atrial area/body surface area
ratio, but diabetic patients had reduced mitral diastolic
peak velocity of the septal mitral annulus, E’,a l s oc o n -
sistent with impaired diastolic function. Although the
higher mitral Doppler flow velocity E wave/E’ ratio of
MetS and diabetic patients did not achieve statistical
significance, the E/E’ ratio for the three patient groups
combined correlated with pulmonary capillary wedge
pressure (r = 0.44, P = 0.03). There were no differences
between the three patient groups with respect to mitral
Doppler flow velocity E and A waves, E/A ratio, or
mitral deceleration time (data not shown).
Total, interstitial and perivascular fibrosis
The mean area of myocardial paraffin sections (3.6-4.8
mm
2) was similar for the different patient groups.
Total and interstitial fibrosis were similar for the three
patient groups, whereas perivascular fibrosis of MetS
and diabetic patients was less than in control patients
(Figures 3, 4). Total collagen I of diabetic patients was
less than for MetS patients, whereas collagen III and
the collagen I/collagen III ratio, as assessed by immu-
nohistochemistry, were similar for the three patient
groups (Figures 5, 6).
Cardiomyocyte width, capillary length density, and
arteriolar dimensions
Cardiomyocyte width, capillary length density, and diffu-
sion radius did not differ between control, MetS and
diabetic patients (Figures 3, 7). Arteriolar wall area/cir-
cumference ratio was measured for arterioles with dia-
meters (average of maximum and minimum diameters
for each arteriole) of 20-80 μm; mean average arteriolar
diameters were 36-37 μm. There were no differences
between the three patient groups in arteriolar wall area/
circumference ratio (Figure 7).
Immunostaining for CML and RAGE
As previously described [33], immunostaining for CML
was predominantly localized to the media and intima of
arterioles and venules (Figure 8) and we found no
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Figure 1 Central venous pressure (A), pulmonary capillary
wedge pressure (B), and cardiac index (C) in control (Con),
metabolic syndrome (MetS), and type 2 diabetic (Diab) men
undergoing coronary artery bypass graft surgery. Data shown
as means ± SEM. Measurements were made immediately after
induction of anesthesia. Pulmonary capillary wedge pressure data
were analyzed with central venous pressure as a covariate because
of its dependence on central venous pressure.
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Page 5 of 14difference in CML expression between the three patient
groups (Figure 9). RAGE immunostaining was predomi-
nantly localized to the intima of arterioles and venules
and to capillaries (Figure 10) and we found no differ-
ence in RAGE expression between the three patient
groups (Figure 9).
Correlations with duration of diabetes, glycemic control,
and insulin resistance
Although the duration of diabetes ranged from 0-30
years, none of the parameters of myocardial structure,
microvasculature, and AGE and RAGE expression corre-
lated with diabetes duration in the diabetic subjects. By
contrast, diabetes duration correlated with the E/E’ ratio
(r = 0.87, P = 0.03), with a weaker non-significant corre-
lation with mitral septal E’ (r = 0.83, P = 0.08).
Among all patients combined, fasting plasma glucose
was positively correlated with the E/E’ ratio (r = 0.46, P
= 0.02), with a weaker non-significant inverse correla-
tion with mitral septal E’ (r = 0.40, P = 0.07), but was
not correlated with any of the parameters of myocardial
structure, microvasculature, or AGE and RAGE expres-
sion. Additionally, neither fasting plasma insulin concen-
trations nor HOMA2-IR was correlated with any
parameter of myocardial structure, microvasculature, or
AGE and RAGE expression.
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Figure 2 Ejection fraction (A), left atrial area/body surface area ratio (B), early diastolic peak velocity of the septal mitral annulus, E’
(C), and the mitral Doppler flow velocity E wave/E’ ratio (D) in control (Con), metabolic syndrome (MetS), and type 2 diabetic (Diab)
men undergoing coronary artery bypass graft surgery. Data shown as means ± SEM. Measurements were made by transthoracic
echocardiography before surgery.
Campbell et al. Cardiovascular Diabetology 2011, 10:80
http://www.cardiab.com/content/10/1/80
Page 6 of 14Discussion
This study investigated the association of type 2 diabetes
and the MetS with myocardial fibrosis (assessed by
picrosirius red staining and immunostaining for collagen
I and III), cardiomyocyte size, capillary length density,
diffusion radius, arteriolar dimensions, and myocardial
expression of CML and RAGE. We confirmed the
impaired diastolic function of type 2 diabetic and MetS
patients [2,34], as shown by their increased pulmonary
capillary wedge pressure and reduced mitral septal E’.
Figure 3 Picrosirius-red staining demonstrating interstitial and
perivascular fibrosis (stained red) and arteriolar dimensions
(A), reticulin staining of cardiomyocyte membranes
demonstrating cardiomyocyte size (B), and CD31 staining of
capillaries (C) of left ventricular biopsies from control coronary
artery bypass graft surgery patients.
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Figure 4 Total myocardial fibrosis (A), interstitial fibrosis (B),
and perivascular fibrosis (C) determined by picrosirius red
staining in left ventricular biopsies from control (Con),
metabolic syndrome (MetS), and type 2 diabetic (Diab) men
undergoing coronary artery bypass graft surgery. Data shown
as means ± SEM.
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Page 7 of 14Figure 5 Immunostaining for collagen I (A), collagen III (B), and
a negative control section without primary antibody (C), of a
left ventricular biopsy from a control coronary artery bypass
graft surgery patient.
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Figure 6 Total collagen I (A), total collagen III (B), and total
collagen I/collagen III ratio (C) determined by immunostaining
in left ventricular biopsies from control (Con), metabolic
syndrome (MetS), and type 2 diabetic (Diab) men undergoing
coronary artery bypass graft surgery. Data shown as means ±
SEM.
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Page 8 of 14Our data demonstrate that the impaired diastolic func-
tion of type 2 diabetic and MetS patients was not
dependent on increased myocardial fibrosis, cardiomyo-
cyte hypertrophy, alteration of the myocardial microvas-
cular structure, or increased myocardial expression of
CML or RAGE. These data suggest that the increased
myocardial fibrosis and CML expression reported by
previous studies of diabetic patients with heart failure
[3,12,21,22,33] were a consequence, rather than an initi-
ating cause, of impaired cardiac function.
Our findings for myocardial fibrosis and CML expres-
sion are in agreement with a recent study by van Heere-
beek et al. [22] who studied endomyocardial LV biopsies
from patients hospitalized with worsening heart failure.
They found no increase in fibrosis or CML expression
in LV biopsies of diabetic subjects with normal LV
ejection fraction, but increased fibrosis and CML
expression in patients with reduced LV ejection fraction
[22]. The present study extends these findings to a
much earlier stage in the evolution of diabetic cardio-
myopathy by study of epicardial LV biopsies from dia-
betic and MetS patients with increased LV filling
pressures without symptomatic heart failure. Although
the diabetic patients had reduced mitral septal E’,w e
found no differences between the three patient groups
for Doppler measures of left ventricular filling or left
atrial size, suggesting that the impairment of diastolic
function was much less than that which occurs in heart
failure with preserved ejection fraction.
Cardiomyocyte size has been reported to be increased
[3,13,17], normal [19], and reduced in diabetic patients
[15]. Our finding of no increase in cardiomyocyte width
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Figure 7 Cardiomyocyte width (A), capillary length density (B), diffusion radius (C), and arteriolar wall area/circumference ratio (D) in
left ventricular biopsies from control (Con), metabolic syndrome (MetS), and type 2 diabetic (Diab) men undergoing coronary artery
bypass graft surgery. Arteriolar wall area/circumference ratio was determined for arterioles with diameter (average of maximum and minimum
diameter of each arteriole) of 20-80 μm. Data shown as means ± SEM.
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Page 9 of 14of diabetic and MetS patients is in agreement with
reports of similar cardiac mass for diabetic and non-dia-
betic individuals [35], and the association between
increased insulin levels and cardiac hypertrophy is lar-
gely accounted for by associations with body size [36].
Moreover, our finding of no effect of diabetes and the
MetS on arteriolar dimensions is in agreement with a
previous autopsy study of myocardial arteries [20]. Our
failure to detect hypertrophy of myocardial arterioles
similar to that reported for small arteries in subcuta-
neous tissue of patients with type 2 diabetes [37] may
be because the arterioles examined in our study were
much smaller in size, and it is also possible that the
effects of diabetes on vascular hypertrophy are different
for different vascular beds. The similar capillary length
density and arteriolar dimensions of diabetic and non-
diabetic patients in this study is in agreement with the
similar myocardial perfusion of diabetic and non-dia-
betic subjects in the fasting state [38,39], although it
does not exclude an effect of diabetes and the MetS on
microvascular function.
Our finding that RAGE expression was predominantly
localized to vascular endothelium and capillaries is in
agreement with previous studies [40], although, to our
knowledge, this is the first comparison of myocardial
RAGE expression in control, diabetic, and MetS patients.
Whereas cell-surface-bound RAGE plays an essential role
in mediating the effects of AGEs, soluble RAGE may act
as an AGE inhibitor, by preventing the binding of AGEs to
the cell-surface-bound RAGE receptor [41]. Our finding of
similar circulating levels of soluble RAGE and cardiac
expression of RAGE suggest RAGE did not participate in
the impaired diastolic function of diabetic and MetS
patients in our study. The similar plasma CML and
LMWF levels of diabetic patients to those of control
patients is in agreement with our previous study [42], and
likely reflects their well-controlled diabetes.
Differences between human and animal models of
diabetes
Our study highlights possible differences between dia-
betic humans and animal models of diabetes. In addition
to the lack of increased myocardial fibrosis, we found no
evidence for the cardiomyocyte and arteriolar hypertro-
phy and reduced myocardial capillary density reported
in animal models of diabetes [7,9-11], which may be
related to poorer diabetic control in animal models.
Alternative mechanisms of impaired diastolic function of
diabetes and the MetS
Many mechanisms other than increased fibrosis, cardio-
myocyte hypertrophy and alteration in myocardial vas-
culature have been proposed to explain the diastolic
dysfunction of diabetes and the MetS. These include
Figure 8 Immunostaining for Nε-(carboxymethyl)lysine (CML) (A) and negative control section without primary antibody (B), of left
ventricular biopsy from control coronary artery bypass graft surgery patient.
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Page 10 of 14alterations in cardiomyocyte metabolism, abnormal cal-
cium homeostasis and contractile mechanisms, oxidative
stress, direct glucotoxicity, and inflammation
[1,2,5,8,22,43,44]. Our data are compatible with a role
for both insulin resistance and hyperglycemia in the
pathogenesis of the diastolic dysfunction of diabetes and
the MetS [2].
Limitations
Our study had a number of limitations. These included
a limited sample size because of the need for myocardial
biopsies from each patient. However, in a separate study
of 11 control, 7 diabetic, and 6 MetS patients with aortic
stenosis we similarly found no association of diabetes or
the MetS with increased myocardial fibrosis or altered
cardiomyocyte width, capillary length density, diffusion
radius, or arteriolar dimensions, although, in comparison
with the patients in this study, aortic stenosis patients
had more interstitial fibrosis, greater cardiomyocyte
width, lower capillary length density, and greater diffu-
sion radius (unpublished data). Another limitation was
the inherent selection bias caused by the sampling of
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Figure 9 N
ε-(carboxymethyl)lysine (CML) in arteriolar media (A) and intima (B), and the receptor for AGEs (RAGE) in arteriolar intima
(C) and capillaries (D) determined by immunostaining in left ventricular biopsies from control (Con), metabolic syndrome (MetS), and
type 2 diabetic (Diab) men undergoing coronary artery bypass graft surgery. Data shown as means ± SEM.
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gery. However, in a comparison of aortic stenosis
patients with and without coronary artery disease we
found no effect of coronary artery disease on myocardial
fibrosis, cardiomyocyte width, capillary length density,
diffusion radius, or arteriolar dimensions (unpublished
data). Patients with coronary artery disease were an
important patient group to study because of the high
prevalence of coronary artery disease in diabetic patients
[45,46], and coronary artery disease patients with dia-
betes are twice as likely as those without diabetes to
develop heart failure [6]. Although the frequent use of
antihypertensive therapy, including inhibitors of the
renin angiotensin system and statin therapy, may have
attenuated the effect of MetS and diabetes on the myo-
cardium, the MetS and diabetic patients in this study
had evidence of diastolic dysfunction. Moreover, dia-
betes remains a predictor of heart failure when these
therapies are included in multivariate analysis [6]. To
avoid the effect of coronary stenoses on myocardial
s t r u c t u r ea n dt h em i c r o v a s c u l a t u r ew et o o kp a r t i c u l a r
care to collect biopsies from the same epicardial region
of the LV myocardium without evidence of ischemia or
wall motion abnormality, which was proximal to signifi-
cant flow-limiting coronary stenoses and collaterals.
However, we do not know if the data obtained apply to
other regions of the myocardium, such as myocardium
distal to significant flow-limiting coronary stenoses. It is
also unknown whether our findings are relevant to the
right ventricle, which may al s oc o n t r i b u t et od i a b e t i c
cardiomyopathy [47]. Moreover, the generalizability of
our findings is limited by the exclusion of women.
Although we had echocardiographic data for only a lim-
ited number of patients we had hemodynamic data,
including ventriculograms and pulmonary capillary
wedge pressures, which provided a direct measure of LV
filling pressure, for all patients.
Conclusions
We compared MetS (pre-diabetic) and diabetic patients
with patients without these conditions in order to examine
the effects of the insulin-resistant state before diabetes
(and anti-diabetes medication) commenced, and the
effects of diabetes before heart failure developed. We
found that the increased LV filling pressures of MetS and
type 2 diabetic patients were not dependent on increased
myocardial fibrosis or alteration in cardiomyocyte size,
capillary length density, diffusion radius, arteriolar dimen-
sions, or myocardial expression of CML and RAGE. Our
findings suggest that the increased myocardial fibrosis and
CML expression, cardiomyocyte hypertrophy, and altered
microvasculature structure previously described in diabetic
heart disease were a consequence, rather than an initiating
cause, of cardiac dysfunction.
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